NCT02452554 (Clinical Trial / Lorvotuzumab Mertansine / BB-10901 / IMGN-901)

Study Title
Lorvotuzumab Mertansine in Treating Younger Patients With Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor, or Synovial Sarcoma (NCT02452554)

Trial Description
This phase II trial studies how well lorvotuzumab mertansine (also known as BB-10901; huN901-DM1,  huN901-SPP-DM1, IMGN-901 or IMGN901 TAP) works in treating younger patients with Wilms tumor, rhabdomyosarcoma, neuroblastoma, pleuropulmonary blastoma, malignant peripheral nerve sheath tumor (MPNST), or synovial sarcoma that has returned or that does not respond to treatment.

Antibody-drug conjugates, such as lorvotuzumab mertansine, are created by attaching an antibody (protein used by the body’s immune system to fight foreign or diseased cells) to an anti-cancer drug. The antibody is used to recognize tumor cells so the anti-cancer drug can kill them.

This trial is sponsored by Children’s Oncology Group/National Cancer Institute (NCI). [1]

Study Data

  • Condition:
    • Pleuropulmonary Blastoma
    • Recurrent Malignant Peripheral Nerve Sheath Tumor
    • Recurrent Neuroblastoma
    • Recurrent Rhabdomyosarcoma
    • Recurrent Synovial Sarcoma Wilms Tumor
  • Interventions:
    • Drugs used in this trial
      • Lorvotuzumab Mertansine ( BB-10901 / IMGN-901)
      • Other: Laboratory Biomarker Analysis
      • Other: Pharmacological Study
  • Phase: II
  • Estimated Enrollment: 150
  • Start: May 2015
  • Estimated Primary Completion: March 2019
  • Last verified: May 2015

Study Schematic 

(Coming soon)

Click here to Return to Drug map

Last Editorial review: August 10, 2015
Information based on (NIH/NCI) and other sources.

Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.